Financial News · Live Terminal

Page 541 of 544

Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating

Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.44, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $138.65, Change: $-0.38, Percent Change: -0.27%

Financial News · Live Terminal

Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating

Mizuho Adjusts Price Target on American International Group to $84 From $86, Maintains Neutral Rating

Mizuho Adjusts Price Target on Atmos Energy to $192 From $180, Maintains Neutral Rating

Raymond James Adjusts Williams PT to $78 From $73, Maintains Outperform Rating

BofA Adjusts Price Target on International Business Machines to $300 From $340, Maintains Buy Rating

Equinor to Propose Share Capital Reduction After 2025 Buyback Program

BofA Adjusts Price Target on MACOM Technology Solutions to $305 From $260, Maintains Buy Rating

ALX Oncology Names Jeff Knight Chief Development, Operating Officer

Raymond James Trims Hewlett Packard Price Target to $29 From $30, Maintains Outperform Rating

BofA Securities Raises Price Target on Analog Devices to $425 From $400, Maintains Buy Rating

Burke & Herbert Financial, Linkbancorp Get Regulatory Approvals for Pending Merger

Mizuho Adjusts Price Target on Marsh & McLennan to $193 From $199, Maintains Neutral Rating

Market Chatter: Goldman Sachs Launches Three-Part Investment-Grade Bond Offering

T. Rowe Price Reports Lower Assets Under Management in March

Rumble Launches Tender Offer for Northern Data Shares

Mizuho Adjusts Price Target on Everest Group to $365 From $360, Maintains Neutral Rating

BMO Capital Adjusts Price Target on Avery Dennison to $222 From $224, Maintains Outperform Rating

BMO Capital Adjusts Price Target on Public Service Enterprise Group to $91 From $90, Maintains Market Perform Rating

Mizuho Adjusts Price Target on Boston Scientific to $90 From $115, Maintains Outperform Rating

Mizuho Adjusts Price Target on ResMed to $255 From $300, Maintains Outperform Rating

Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating

Mizuho Adjusts Price Target on American International Group to $84 From $86, Maintains Neutral Rating

Mizuho Adjusts Price Target on Atmos Energy to $192 From $180, Maintains Neutral Rating

Raymond James Adjusts Williams PT to $78 From $73, Maintains Outperform Rating

BofA Adjusts Price Target on International Business Machines to $300 From $340, Maintains Buy Rating

Equinor to Propose Share Capital Reduction After 2025 Buyback Program

BofA Adjusts Price Target on MACOM Technology Solutions to $305 From $260, Maintains Buy Rating

ALX Oncology Names Jeff Knight Chief Development, Operating Officer

Raymond James Trims Hewlett Packard Price Target to $29 From $30, Maintains Outperform Rating

BofA Securities Raises Price Target on Analog Devices to $425 From $400, Maintains Buy Rating

Burke & Herbert Financial, Linkbancorp Get Regulatory Approvals for Pending Merger

Mizuho Adjusts Price Target on Marsh & McLennan to $193 From $199, Maintains Neutral Rating

Market Chatter: Goldman Sachs Launches Three-Part Investment-Grade Bond Offering

T. Rowe Price Reports Lower Assets Under Management in March

Rumble Launches Tender Offer for Northern Data Shares

Mizuho Adjusts Price Target on Everest Group to $365 From $360, Maintains Neutral Rating

BMO Capital Adjusts Price Target on Avery Dennison to $222 From $224, Maintains Outperform Rating

BMO Capital Adjusts Price Target on Public Service Enterprise Group to $91 From $90, Maintains Market Perform Rating

Mizuho Adjusts Price Target on Boston Scientific to $90 From $115, Maintains Outperform Rating

Mizuho Adjusts Price Target on ResMed to $255 From $300, Maintains Outperform Rating